Drug Developers Look to Deuterated Drugs as Risk Managed Opportunity

(Amherst, NH) – Interest in deuterated drugs – drugs in which carbon-hydrogen bonds have been replaced with carbon-deuterium (heavy hydrogen) bonds - has been increasing as drug companies seek to shorten the path to market by modifying existing APIs that have established clinical value. The ability of developers to employ formulation technology to substitute deuterium atoms into an existing drug molecule is seen as a way to lower drug development risk, although the need to establish specific therapeutic efficacy and safety still remain.

Recently, the number of articles about deuterated drugs has moved to a new level following FDA approval of Teva’s Austedo for the treatment of chorea associated with Huntington’s disease. One of the often-cited advantages of replacing hydrogen with deuterium is the effect that heavy hydrogen atoms can have on drug half-life. To the extent that the drug remains in the system longer there is the possibility that dosing frequency can be reduced.

Currently, there are about a dozen companies actively pursuing the deuterated drug market. The majority are smaller drug formulators and developers, often relying on partnerships for co-development and/or marketing and distribution. Patents are expected to play a major role in this segment, largely because the majority of deuterated drugs under development are approved APIs in undeuterated form. This dynamic has given rise to a significant level of defensive IP activity, in which companies patent deuterated APIs largely on speculation that the drug will prove to be efficacious and safe at some point in the future.

The potential for defensive acquisition and investment is also factoring into the response of existing API rights holders. In this scenario, a non-deuterated API patent holder may invest in a company in the deuterated drug space that is developing a deuterated version of the API, giving the investing company the ability to leverage the timing of an eventual FDA filing to minimize the negative competitive impact of a deuterated product version on existing product revenue.

There are currently about two dozen potentially important deuterated drugs in development. Many of these drugs are pursuing therapeutic targets in important markets that include neurotransmitter regulation, transmembrane conductance, protease inhibition, inflammation, mitochondrial function modulation and antineoplasticity.

The findings of a recent survey of the deuterated drug market are detailed in a new and comprehensive report researched and written by Greystone Research Associates. Deuterated Drugs: Products, Pipelines, Strategies, Therapeutics and Markets has been created to provide readers with information and data to assist them in understanding and effectively evaluating the market and competitive landscape for deuterated drugs. The report includes technology assessments, therapeutic target analysis, patent and product positioning strategies, therapeutic factors, near-term markets and market participant profiles.

More information is available at http://www.greystoneassociates.org

Source: Greystone Research Associates

About Greystone

Greystone Research Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.

Contact:

Mark Smith
Greystone Research Associates
98 Route 101A
Amherst, NH 03031 USA
Voice: 603-595-4340
Fax: 603-218-7020
mksmith@drug-strategies.com
www.greystoneassociates.org

This release was published on openPR.